This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cramer's 'Mad Money' Recap: Next Week's Game Plan (Final)

Speculative Medical Device Play

For "Speculation Friday," Cramer once again looked towards the medical device makers for a safe place to speculate. He said these stocks are primarily domestic, with little international exposure, have no generic competition like the drug stocks, and have found favor in Washington.

Among the group, Cramer singles out Heartware (HTWR) as his favorite. He said that Heartware makes devices to help those waiting for heart transplants, and with 5 million people in the U.S. suffering from heart disease, the market opportunity is growing.

Heartware is waiting for FDA approval for its lastest assistive device, a device that's already been deemed superior in Europe, with a 90% survival rate versus only 78% for the competing device made by Thoratec (THOR), of which Cramer is not a fan. Cramer said the Heartware device is clearly superior, with a faster surgery, faster recover and fewer complications.

Cramer was also a fan of Heartware gaining approval for "destination therapies," devices that forgo the need for a transplant altogether. Approval for destination therapies is expected in 2013.

Shares of Heartware are $15 off their $99 high, and Cramer said that makes this speculative name a steal.

A Lot to Like

Continuing with "Speculation Friday," Cramer also highlighted Tornier (TRNX - Get Report), a little known orthopedic company that makes implants for extremities such as shoulders, feet, wrists and ankles. Tornier came public last month at $18 a share, and since then, Cramer said investors haven't missed much.

But there's a lot to like about Tornier, said Cramer. The company pretty much dominates the markets in which it competes since many of the bigger players have deemed extremities too small to be profitable. Tornier is expected to introduce a whopping 19 new products in 2011, helping the company reach profitability by 2012.

Cramer said Tornier is interesting as a speculation now, before its profitable, because shares trade at just 2.5 times sales. Based on recent analyst estimates, the value of Tornier's different businesses values the company between $23 and $25 a share. Given its many new product introductions, and its expansion into China, South America and Japan, Cramer said investors shouldn't wait for Tornier to break even.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
DXCM $71.64 0.00%
LLNW $4.25 0.00%
PODD $28.06 0.00%
SLB $91.00 0.00%
SBUX $51.59 0.00%

Markets

DOW 18,162.99 +121.45 0.67%
S&P 500 2,123.48 +19.28 0.92%
NASDAQ 5,106.5930 +73.8420 1.47%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs